Search

Your search keyword '"Soliman, Ahmed A."' showing total 298 results
Start Over Author "Soliman, Ahmed A." Publisher elsevier b.v.
298 results on '"Soliman, Ahmed A."'

20. Influence of Diclofenac Potassium versus Prednisolone on Postendodontic Pain and Pulpal Interleukin-8 Expression in Symptomatic Irreversible Pulpitis Cases: A Randomized Placebo-controlled Trial.

Author

Soliman, Ahmed Adel, Ezzat, Khaled Mohamed, Shaker, Olfat Gamil, and Abouelenien, Sarah Samir

Subjects
ONE-way analysis of variance, FISHER exact test, VISUAL analog scale, INTERLEUKIN-8, RANK correlation (Statistics)
Abstract

This prospective, randomized, double-blind clinical trial investigated the impact of diclofenac potassium, prednisolone, and placebo as oral premedication on postendodontic pain and pulpal interleukin (IL)-8 expression in patients with irreversible pulpitis. Thirty-six patients undergoing conventional endodontic treatment were assigned into one of 3 groups (n = 12). Pulpal blood samples were taken after access cavity preparation and stored until they were analyzed using enzyme-linked immunosorbent asssay for quantification of IL-8. Postendodontic pain was scored using the visual analogue scale. Outcome data were statistically analyzed using one-way analysis of variance, Kruskal-Wallis, Friedman's, Dunn's, Chi-square, and Fisher's exact tests and Spearman's correlation coefficient. The significance level (α) was set at 0.05. Apart from preoperative pain scores, all groups had similar baseline characteristics (P >.05). Immediate postendodontic pain scores had a significant difference between all groups (P <.05) where placebo group showed the highest score. There was no significant difference between all groups at 6 and 12 hours postoperatively (P >.05). Furthermore, there was no significant difference in the incidence of postendodontic pain and in mean IL-8 levels between the 3 groups (P >.05). The only impact the premedications had was on the immediate postendodontic pain intensity, and they had no influence on the later time points, incidence of postendodontic pain or pulpal IL-8 levels. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

49. Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up.

Author

Papp, Kim A., Blauvelt, Andrew, Puig, Lluís, Ohtsuki, Mamitaro, Beissert, Stefan, Gooderham, Melinda, Amin, Ahmad Z., Liu, Jie, Wu, Tianshuang, Azam, Tofial, Stakias, Vassilis, Espaillat, Ramon, Sinvhal, Ranjeeta, Soliman, Ahmed M., Pang, Yinuo, Chen, Michael M., and Lebwohl, Mark G.

Abstract

Psoriasis is a chronic, inflammatory skin disease often requiring long-term therapy. To evaluate the long-term safety and efficacy of risankizumab in patients with psoriasis. LIMMitless is an ongoing phase 3, open-label extension study evaluating the long-term safety and efficacy of continuous risankizumab 150 mg every 12 weeks for adults with moderate-to-severe plaque psoriasis following multiple phase 2/3 base studies. This interim analysis assessed safety (ie, monitored treatment-emergent adverse events [TEAEs]) through 304 weeks. Efficacy assessments included determining the proportion of patients who achieved ≥90% or 100% improvement in Psoriasis Area and Severity Index (PASI 90/100), static Physician's Global Assessment of clear/almost clear (sPGA 0/1), and Dermatology Life Quality Index of no effect on patient's life (DLQI 0/1) through 256 weeks. Among 897 patients randomized to risankizumab in the base studies, 706 were still ongoing at data cutoff. Rates of TEAEs, TEAEs leading to discontinuation, and TEAEs of safety interest were low. At week 256, 85.1%/52.3% of patients achieved PASI 90/100, respectively, 85.8% achieved sPGA 0/1, and 76.4% achieved DLQI 0/1. Open-label study with no placebo or active-comparator group. Long-term continuous risankizumab treatment for up to 5 years was well tolerated and demonstrated high and durable efficacy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results